Biotechnology company specializing in investigating the anti-inflammatory effects of psilocybin in less researched metabolic conditions Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) announced that the United States Food and Drug Administration (FDA) has approved its orphan drug application to use proprietary psilocybin drug to treat patients with fragile X syndrome (FXS).
The fragile X syndrome is the most common inherited cause of autism spectrum disorder (ASD). The company’s president and chief executive officer, Will Rascan, says the company is the first ever to register treatment of FXS with both the FDA and European Medical Agency (EMA).
“NOVA has established a unique position in the field of psychedelic therapy by having its FXS program achieve orphan drug status in both the United States and European Union. I am pleased to announce that we are the first biotech company to have psilocybin registered for treatment of FXS in the drug regulatory logs of both the FDA and EMA,” said the CEO.